The Acute Erythroleukemias

Mazzella, Fermina M.; Alvares, Carmelita J.; Kowal-Vern, Areta; Schumacher, Harold R.

doi:10.1016/s0272-2712(18)30080-5

Cited by 25 publications

(25 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the study referred by the 2008 WHO for the definition of PEL consisting of eight cases of minimally differentiated erythroleukemia, the inclusion criteria were Z50% immature erythroblasts with o10% 'differentiating' forms. 5 In contrary, Mazzella and colleagues 6,15,16 have consistently used 30% pronormoblasts of erythroid precursors as the cutoff to define PEL. In 2002, Domingo-Claros et al 17 studied 62 cases of acute erythroid neoplastic proliferation by using the 2001 WHO criteria.…”

Section: Discussionmentioning

confidence: 99%

Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification

Liu

Hasserjian

et al. 2011

Modern Pathology

View full text Add to dashboard Cite

Pure erythroid leukemia (PEL) is rare, characterized by a neoplastic proliferation of erythroblasts. Given recent incorporation of molecular genetic findings and clinical features in the revised 2008 World Health Organization classification scheme of acute myeloid leukemia, we questioned if PEL still remains as a distinct subtype of acute myeloid leukemia. In this retrospective study, we identified 18 cases of acute leukemia with morphologic and immunophenotypic features of PEL. Following the current World Health Organization classification algorithm, these cases were classified as: 13 acute myeloid leukemia with myelodysplasia-related changes, 3 therapy-related acute myeloid leukemia, and 1 chronic myelogenous leukemia blast crisis, and one unclassifiable due to insufficient clinical information. All 16 cases with cytogenetic data harbored an extremely complex karyotype and the median overall survival of the 18 patients was 3 months (range, 1-7 months). This survival was significantly shorter than that of patients with acute erythroid leukemia, erythroid/myeloid subtype, or acute myeloid leukemia with myelodysplasia-related changes with erythroid predominance (Po0.001). PEL is characterized as a neoplastic erythroid hyperproliferation with maturation arrest. E-cadherin emerged as the most sensitive and specific marker for immature erythroblasts, and was helpful in distinguishing PEL from other erythroid proliferations. Our study showed that the criteria for acute myeloid leukemia in the 2008 World Health Organization system facilitate reclassification of PEL cases into other acute myeloid leukemia categories, mainly of acute myeloid leukemia with myelodysplasia-related changes. These new assigned categories fail to capture the distinct features of PEL, where the phenotype of PEL correlates with a very complex karyotype and an extremely aggressive clinical course.

show abstract

Section: Discussionmentioning

confidence: 99%

Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification

Liu

Hasserjian

et al. 2011

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…Dysgranulopoiesis is described in half of the patients. 9 This heterogeneity of trilineage dysplasia can be explained by the fact that erythroleukemia includes primary and secondary diseases.…”

Section: Clinical Presentationmentioning

confidence: 99%

Erythroleukemia: a need for a new definition

2002

View full text Add to dashboard Cite

The new WHO classification abolishes the frontier between RAEB-t with 20% of blasts and leukemia with 30% of blasts. We review the definitions of erythroleukemia and discuss the relationship between FAB AML6, RAEB-t and AML6 variant. We ask whether secondary erythroleukemias are the same entity as RAEB-t on survival, karyotype and cytologic characteristics. We suggest that 'AML6 variant' with pure erythroid lineage proliferation would be the real de novo erythroleukemia. Current FAB AML6 entity will probably be classified in either subgroup (1) multilineage dysplasia; (2) therapy-related leukemia; or (3) acute erythroid leukemia subdivided into erythroleukemia (erythroid/myeloid) and pure erythroid leukemia, in the WHO classification -a classification which highlights the importance of clinical and cytogenetic prognostic factors.

show abstract

“…Erythroleukemia is one of the the eight subtypes of acute myeloid leukemia (AML). It was first described by Di Guglielmo in the early twentieth century [30], it is characterized by a proliferation of erythroid and myeloid (white cells) progenitors, and sometimes a pure erythroid proliferation is observed [27]. A dysfunction of the Epo-mediated apoptosis has been stressed to be a causative agent of erythroleukemia.…”

Section: Regulation Of Normal Erythropoiesismentioning

confidence: 99%

Hybrid Model of Erythropoiesis and Leukemia Treatment with Cytosine Arabinoside

Kurbatova

Bernard²,

Bessonov³

et al. 2011

SIAM J. Appl. Math.

View full text Add to dashboard Cite

Abstract. A hybrid model of cell population dynamics, where cells are discrete elements whose dynamics depend on continuous intracellular and extracellular processes, is developed to simulate the evolution of immature red blood cells in the bone marrow. Cell differentiation, self-renewal or apoptosis are determined by an intracellular network, based on two proteins, Erk and Fas, and described by ordinary differential equations, and by local extracellular regulation performed by Fasligand, a protein produced by mature cells whose concentration evolution is represented by a partial differential equation. The model is used to study normal and leukemic red blood cell production (erythropoiesis), and treatment of leukemia. Normal cells are assumed to have a circadian rhythm that influences their cell cycle progression, whereas leukemic cells, are assumed to escape circadian rhythms. We consider a treatment based on periodic administration of Ara-C, an anti-cancer agent targeting cells in DNA synthesis. A detailed pharmacodynamic/pharmacokinetic model of Ara-C is proposed and used to simulate the treatment. Influence of the period of the treatment and the day delivery time on the outcome of the treatment is investigated and stress the relevance of considering chronotherapeutic treatments to treat leukemia.

show abstract

The Acute Erythroleukemias

Cited by 25 publications

References 50 publications

Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification

Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification

Erythroleukemia: a need for a new definition

Hybrid Model of Erythropoiesis and Leukemia Treatment with Cytosine Arabinoside

Contact Info

Product

Resources

About